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ABSTRACT 
Ca2+/calmodulin-dependent protein kinase kinase (CaMKK) activates particular multifunctional 
kinases including CaMKI, CaMKIV, and 5’AMP-activated protein kinase (AMPK), resulting in 
the regulation of various Ca2+-dependent cellular processes including neuronal, metabolic, and 
pathophysiological pathways. Herein we developed and characterized a novel pan-CaMKK 
inhibitor, TIM-063 (2-hydroxy-3-nitro-7H-benzo[de]benzo[4,5]imidazo[2,1-a]isoquinolin-7-one 
) derived from STO-609 (7H-benzimidazo[2,1-a]benz[de]isoquinoline-7-one-3-carboxylic acid), 
and an inactive analog (TIM-062) as molecular probes for the analysis of CaMKK-mediated 
cellular responses. Unlike STO-609, TIM-063 had an inhibitory activity against CaMKK isoforms 
(CaMKKα and β) with a similar potency (Ki = 0.35 µM for CaMKKα and Ki = 0.2 µM for 
CaMKKβ) in vitro. Two TIM-063 analogues lacking a nitro group (TIM-062) or a hydroxy group 
(TIM-064) completely impaired CaMKK inhibitory activities, indicating that both substituents are 
necessary for the CaMKK inhibitory activity of TIM-063. Enzymatic analysis revealed that TIM-
063 is an ATP-competitive inhibitor that directly targets the catalytic domain of CaMKK, similar 
to STO-609. TIM-063 suppressed the ionomycin-induced phosphorylation of exogenously 
expressed CaMKI, CaMKIV and endogenous AMPKα in HeLa cells with an IC50 of ~0.3 µM, and 
it suppressed the CaMKK isoforms-mediated CaMKIV phosphorylation in transfected COS-7 
cells. Thus, TIM-063, but not the inactive analogue (TIM-062), displayed cell permeability and 
the ability to inhibit CaMKK activity in cells. Taken together, these results indicate that TIM-063 
could be a useful tool for the precise analysis of CaMKK-mediated signaling pathways and may 
be a promising lead compound for the development of therapeutic agents for the treatment of 
CaMKK-related diseases. 
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INTRODUCTION 
Ca2+/calmodulin-dependent protein kinase kinase (CaMKK) was originally identified as an 
activating kinase for CaMKI and CaMKIV, phosphorylating their activation loop threonine 
residues (Thr177 in CaMKIα and Thr196 in CaMKIV)(1-4). In addition, CaMKK was later found 
to activate PKB/Akt in various cell lines including NG108 neuroblastoma cells, human embryonic 
kidney (HEK) 293 cells, LNCaP prostate cancer cells, and ovarian cancer cell lines including 
OVCAR-3 cells (5-8). Furthermore, 5’AMP-activated protein kinase (AMPK) is activated by 
CaMKKβ via the phosphorylation of Thr172 in the catalytic subunit (α subunit), which plays an 
important role in regulating cell energy metabolism (9-11). CaMKK is a member of CaM-
dependent kinase family, which is regulated by an intrasteric autoinhibition and activated by 
Ca2+/CaM binding to the regulatory domain in a similar manner to other CaMKs (12, 13), although 
it is not genetically classified as a member of the CaMK family (14). CaMKK-mediated Ca2+-
signaling plays an important role in various neuronal activities (15-23), metabolic responses (24-
26), and pathophysiological responses including cancer cell growth (8, 27) and proliferation (28). 
CaMKKβ-mediated AMPK activation is involved especially in cell growth of various cancers 
including prostate (29) and lung cancers (30) as well as metabolically-related hepatic diseases (31). 
Therefore, CaMKKβ could be a promising molecular target for the treatment of these diseases. 
In 2002, the first CaMKK inhibitor STO-609 (7H-benzimidazo[2,1-a]benz[de]isoquinoline-7- 
one-3-carboxylic acid) was developed by our laboratory members (32), and it has been widely 
used to demonstrate the involvement of CaMKK activity in various Ca2+-dependent 
physiological responses mediated by CaMKK/CaMKI, CaMKK/CaMKIV, CaMKK/AMPK, 
and CaMKK/PKB (Akt) pathways (9-11, 15-17, 33-37). Previous studies have reported the in 
vivo use of STO-609 for the inhibition of CaMKK2 (β) in the control of satiety (24) that was 
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confirmed using a recently developed orally bioavailable CaMKK2 inhibitor, compound 4t (38), 
as well as to confer protection against prostate cancer (29), liver cancer (27), and non-alcoholic 
fatty liver disease (31). Recently, STO-609 has been shown to attenuate mammary tumor growth 
in immunocompetent mice (39). Like other protein kinase inhibitors, STO-609 is a cell-
membrane-permeable ATP-competitive inhibitor (32). Therefore, several protein kinases 
including casein kinase 2, AMPK, and MAPK-interacting kinase 1 are inhibited by STO-609 
with a 10-fold lower potency to inhibit CaMKKβ (40). Accordingly, although STO-609 is 
relatively selective but not specific to CaMKKs, it is still useful for the evaluation of the 
physiological functions of CaMKK in cells because of the successful development of inhibitor-
resistant mutants (16, 41, 42). Because STO-609 preferably inhibits CaMKKβ rather than 
CaMKΚα (32,40,41), the specific role of CaMKKα is difficult to ascertain by pharmacological 
approaches using an inhibitor. Thus, a distinct type of CaMKK inhibitor must be developed to 
examine the physiological roles of CaMKK isoforms. To date, the structure–function study of 
STO-609 to develop an STO-609-related CaMKK inhibitor has not been performed. Therefore, 
in this study, we attempted to synthesize STO-609 derivatives as CaMKK inhibitors. We 
discovered a compound that potently suppresses the activities of both CaMKK isoforms equally 
in vitro as well as in cultured cells together with a closely-related inactive compound. 
 
MATERIALS AND METHODS 
Materials. Recombinant rat CaMKKα and β (wild type) were expressed in E. coli BL21 Star 
(DE3) and purified by CaM-Sepharose and Q-Sepharose chromatographies (43). GST-rat 
CaMKKα (126–434) and GST-rat CaMKKβ (162–470) were expressed in E. coli BL21 Star (DE3) 
cells and purified as previously described (41). GST-rat CaMKIα 1–293 Lys49Glu (GST-CaMKI 
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1–293 KE, kinase dead mutant) was expressed in E. coli JM109 and purified as described 
previously (12). GST-fused enzymes were purified with glutathione-sepharose (GE Healthcare 
Life Sciences, Buckinghamshire, England) chromatography.  Recombinant rat CaM was 
expressed in E. coli BL21 (DE3) using the plasmid pET-CaM (kindly provided by Dr. Nobuhiro 
Hayashi, Tokyo Institute of Technology, Yokohama, Japan) (44). The catalytic subunit of cAMP-
dependent protein kinase from bovine cardiac tissue was kindly provided by Dr. Yasuo Watanabe 
(Showa Pharmaceutical University, Tokyo, Japan). Rat CaMKII holoenzyme was purified from 
rat forebrain as previously described (32). Recombinant rat CaMKIα and mouse CaMKIV were 
expressed in E. coli., purified, and activated by phosphorylation with CaMKKβ in the presence 
of Ca2+/CaM as previously described (45). Anti-phospho-CaMKIα at Thr177 (clone 9H8) and 
anti-phospho-CaMKIV at Thr196 (clone 8D4) monoclonal antibodies were generated as 
previously described (45). Anti-HA antibody (12CA5) was obtained from Roche Applied Sciences 
(Indianapolis, IN). Anti-phospho-AMPKα at Thr172 (2535L) and anti-AMPKα (2532) antibodies 
were purchased from Cell Signaling Technology (Danvers, MA). STO-609 was purchased from 
Tocris Bioscience (Ellsville, MO). All other chemicals were obtained from standard commercial 
sources. 
 
Synthesis of STO-609 Analogues. TIM-055 through TIM-061 was prepared by the reported 
procedure (46). TIM-062, TIM-063, and TIM-064 were synthesized from corresponding 1,8-
naphthalenedicaroxylic anhydride derivatives (1–3) by cyclization reaction with o-
phenylenediamine in tetrahydrofuran (THF) under reflux (Scheme 1). Derivatives (1) and (3) are 
commercially available compounds, and 3-hydroxy-4-nitro-1,8-naphthalenedicaroxylic anhydride 
(2) was prepared by nitration of (1) with trifluoroacetic anhydride and ammonium nitrate at room 
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temperature. Structures of these final products were confirmed by 1H and 13C NMR as well as mass 
spectrometry (see Supporting Information S1). 
 
NMR Spectroscopy.  NMR spectra were recorded on a Varian MERCURY-300 (300 MHz for 
1H and 75 MHz for 13C), using the solvent peak as the internal reference (CDCl3: δ H 7.26; δ C 
77.0; DMSO-d6: δ H 2.50; δ C 39.5). Multiplicities are indicated as s (singlet), d (doublet), t 
(triplet), q (quartet), m (multiplet), and br (broad). Coupling constants (J) are given in Hertz (Hz). 
Mass spectra were recorded on an Agilent Q-TOF G6520. 
 
In Vitro CaMKK Activity Assay.  CaMKK activity was measured at 30°C for 10 min in a 
solution (25 µL) containing 30 ng CaMKKβ or 3 ng CaMKKα, 50 mM HEPES pH 7.5, 10 mM 
Mg(CH3COO)2, 1 mM DTT, 100 µM [γ-32P]ATP (795–2294 cpm/pmol, PerkinElmer Life 
Sciences, Waltham, MA) or indicated concentrations of [γ-32P]ATP and 12.5 µg GST-CaMKI 1–
293 Lys49Glu in the presence of 2 mM CaCl2/6 µM CaM. Each reaction was initiated by the 
addition of [γ-32P]ATP. Reactions were terminated by spotting the samples (20 µL) onto P81 
phosphocellulose paper (Whatman) to measure the 32P incorporation into the substrate. Specific 
activities of CaMKKα and CaMKKβ in the absence of compounds (5% DMSO) were calculated 
to be 451 ± 78 nmol/min/mg and 126 ± 24 nmol/min/mg, respectively. The autophosphorylation 
of CaMKKα and β was measured at 30°C for 120 min in 20 µL of a solution containing 1 µg 
CaMKK isoforms, 50 mM HEPES pH 7.5, 10 mM Mg(CH3COO)2, 1 mM DTT, 100 µM [γ-
32P]ATP in the presence of 2 mM CaCl2/6 µM CaM (for CaMKKα) or 2 mM EGTA (for 
CaMKKβ) with or without compounds. The reaction was terminated by addition of SDS-PAGE 
sample buffer and subjected to SDS-PAGE, followed by autoradiography. 32P incorporation into 
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CaMKK isoforms was estimated by densitometric scanning of the autoradiogram with ImageJ 
software (47). 
 
Protein Kinase Assays.  Protein kinase activities of activated CaMKI (2 ng), CaMKII (10 ng), 
activated CaMKIV (6.3 ng), and PKA (125 ng) were measured at 30°C for 10 min in a solution as 
described for the CaMKK assay without or with TIM-compounds using either peptide substrate 
(40 µM Syntide-2 for CaMKI, CaMKII, and CaMKIV; 40 µM Kemptamide for PKA) in the 
presence of 2 mM CaCl2/6µM CaM (except for PKA) and 100 µM [γ-32P]ATP as previously 
described [32]. Specific activities of activated CaMKI, CaMKII, activated CaMKIV, and PKA in 
the absence of TIM-compounds (5% DMSO) were calculated to be 5450 ± 344, 110 ± 5, 263 ± 14, 
and 9.3 ± 0.8 nmol/min/mg, respectively. 
 
Cell Culture and Transfection.  HeLa and COS-7 cells were cultured in Dulbecco’s modified 
Eagle’s medium supplemented with 10% fetal bovine serum at 37°C in 5% CO2. HeLa cells in 6-
well dishes were transfected with 1 µg of HA-rat CaMKIα (pME-HA-CaMKIα) or 0.25 µg of HA-
mouse CaMKIV (pME-HA-CaMKIV) expression plasmid, and COS-7 cells were transfected with 
1 µg of pME-HA-CaMKIV in the absence or presence of 0.5 µg of rat CaMKKα or β expression 
plasmid (pcDNA3-FLAG-CaMKKα or pME-CaMKKβ) using polyethylenimine “MAX” 
(Polysciences, Inc. Warrington, PA, USA) according to the manufacturer’s protocol. After 42 h, 
the cells were cultured in the absence of serum with indicated concentrations of TIM-compounds 
for 6 h, followed by treatment with 1 µM of ionomycin for 5 min. Then cells were lysed with 1´ 
SDS-PAGE sample buffer (100 µL), followed by immunoblot analyses (5–10 µL cell lysates). 
 
                                                
                                                                      
 8 
Other Methods.  Immunoblot analysis was performed with the indicated primary antibodies and 
horseradish peroxidase-conjugated anti-mouse IgG or anti-rabbit IgG (GE Healthcare Life 
Sciences) as the secondary antibody. A chemiluminescent reagent (PerkinElmer Life Sciences, 
Waltham, MA) was used for signal detection of immunoblots, followed by quantification of the 
immunoreactivity with ImageJ software (47). Protein concentrations in samples were estimated by 
Coomassie Brilliant Blue (Bio-Rad Laboratories, Inc. Hercules, CA), using bovine serum albumin 
as a standard. Student’s t tests were used to evaluate the statistical significance of two-group 
comparisons. Probability (p) values < 0.05 were considered statistically significant. 
 
RESULTS 
Characterization of STO-609 Derivatives as CaMKK Inhibitors.  To develop a novel 
CaMKK inhibitor, we attempted to synthesize compounds derived from STO-609 and 
characterize them as CaMKK inhibitors in vitro and in cultured cells. First, we synthesized 10 
compounds that were analogues of STO-609 with different substitutions at positions R1, R2 and 
R3 (Fig. 1A) and evaluated their inhibitory potencies at a concentration of 10 µg/mL (27–35 
µM) against recombinant CaMKKα and CaMKKβ kinase activities in vitro using GST-CaMKI 
catalytic domain (1-293 Lys49Glu, kinase dead mutant) as a substrate (Fig. 1B).  
Among the STO-609 derivatives, only TIM-063 inhibited approximately 90% of both CaMKKα 
and CaMKKβ activities at a concentration of 10 µg/mL (30 µM), to the same extent as STO-
609 (27 µM). Two TIM-063 analogues lacking either a nitro group at the R2 position (TIM-062) 
or a hydroxy group at R1 (TIM-064) showed no CaMKK inhibitory activity, thereby indicating 
that both substituents are required for the suppression of CaMKK activity by TIM-063. Therefore, 
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we further analyzed TIM-063 as a novel CaMKK inhibitor and TIM-062 and TIM-064 as inactive 
analogues. 
 
Inhibition of CaMKKα and CaMKKβ Activities by TIM-063.  We evaluated the dose-
dependent inhibition of TIM-063 using acetic acid salt of the compound (see Supporting 
Information S1) against the activities of recombinant rat CaMKKα and β isoforms (Fig. 2A). TIM-
063 was capable of inhibiting CaMKKα activity (IC50 = 0.63 µM) with a similar potency as STO-
609 (IC50 = 0.91 µM, Fig. 2A, left panel). In contrast to STO-609 that inhibits CaMKKβ activity 
5–10-fold more effectively than against CaMKKα activity (Fig. 2A) (32, 40), TIM-063 suppresses 
CaMKKβ with an IC50 of 0.96 µM (Fig. 2A, right panel) indistinguishably from its inhibitory 
potency toward CaMKKα (Fig. 3A, left panel). We confirmed that TIM-062 and TIM-064 were 
incapable of inhibiting the activities of both CaMKK isoforms at least up to 10 µg/mL (29 µM and 
27 µM, respectively), which is consistent with the results shown in Fig. 1B.  Next, we checked 
the effect of TIM-063 and inactive analogues (TIM-062 and -064) on the autophosphorylation 
activities of CaMKK isoforms (Fig. 2B and 2C). Because previous studies have shown that 
CaMKKβ undergoes Ca2+/CaM-independent intramolecular autophosphorylation (48), we tested 
the effects of the compounds on the autophosphorylation activity of CaMKKβ in the absence of 
Ca2+/CaM (Fig. 2B and 2C, right panel). As shown in Fig. 2B, right panel, TIM-063 suppressed 
the Ca2+/CaM-independent autophosphorylation activity of CaMKKβ with an IC50 value of 0.66 
µM, which is a similar inhibitory potency as the substrate -phosphorylation activity of CaMKKβ 
(Fig. 2A, right panel). Furthermore, TIM-063 suppressed Ca2+/CaM-dependent 
autophosphorylation of CaMKKα (Fig. 2B, left panel) as its inhibition of substrate 
phosphorylation (Fig. 2A, left panel). These results indicate that TIM-063 is neither a CaM 
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antagonist nor a competitor with respect to protein substrates. In addition, we observed that up to 
10 µg/mL of TIM-062 and TIM-064 (29 µM and 27 µM, respectively) had no or minor effect on 
CaMKKα and β autophosphorylation activities (Fig. 2C). When we examined the effect of TIM-
063 on the activities of cAMP-dependent protein kinase (PKA) and multifunctional Ca2+/CaM-
dependent protein kinases including CaMKI, CaMKII, and CaMKIV using 100 µM [γ-32P]ATP 
(Table I), the activities of PKA, CaMKI and CaMKIV were slightly affected by the presence of 26 
µM TIM-063 (10–30% inhibitory rate). CaMKII activity was suppressed by TIM-063 with 15–
22-fold less potency (IC50 = 14 µM) than that required for CaMKK isoforms. Both TIM-062 and 
TIM-064 exhibited no significant inhibition up to 10 µg/mL (29 µM and 27 µM, respectively) 
against all protein kinases we tested. In addition, TIM-063 was incapable of inhibiting CaMKI and 
CaMKIV activities in the presence of Ca2+/CaM, also supporting that the compound is unlikely a 
CaM antagonist. 
 
TIM-063, an ATP-Competitive Inhibitor.  To ascertain whether TIM-063 directly targets the 
catalytic domains of the CaMKK isoforms, we tested the effect of TIM-063 on the activities of the 
GST-CaMKKα catalytic domain (residues 126–434) and GST-CaMKKβ catalytic domain 
(residues 162–470) mutants that lack autoinhibitory and CaM-binding domains (Fig. 3A) (16, 41, 
42). The inhibitory potencies of TIM-063 against the catalytic domain mutants of the CaMKK 
isoforms were indistinguishable from the full-length enzymes. These results clearly indicated that 
TIM-063 is a direct inhibitor targeting the catalytic domain of the CaMKK isoforms. Because 
STO-609 has shown to be an ATP-competitive inhibitor (32), we expected that TIM-063 also 
would inhibit CaMKK activity competitively with respect to ATP. To test this, we performed a 
CaMKK kinase assay with varying concentrations of ATP (25–200 µM) in the absence or presence 
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of 0.84 µM TIM-063. Lineweaver–Burk plots of CaMKK inhibition by TIM-063 (Fig. 3B) 
indicated that the apparent Km values for ATP of both CaMKK isoforms were increased by the 
addition of TIM-063 without a significant effect on Vmax values. Thus, these results strongly 
suggest that TIM-063 is an ATP-competitive inhibitor. Based on the kinetic data (Fig. 3B), the Ki 
values of TIM-063 were calculated to be 0.35 µM for CaMKKα, comparable to that of STO-609 
(32) and 0.2 µM for CaMKKβ (Supplemental Figure S2). 
 
Suppression of Endogenous CaMKK Activity in HeLa Cells by TIM-063.  To test whether 
TIM-063 inhibits CaMKK activity in intact cells, we monitored phosphorylation of CaMKK 
targets including endogenous AMPK at Thr172 and exogenously expressed HA-CaMKIα and HA-
CaMKIV in HeLa cells, which are induced by an increasing concentration of Ca2+ (Fig. 4). After 
the cells were treated with 1 µM ionomycin for 5 min, phosphorylation of CaMKK-target kinases 
was monitored by immunoblot analysis using each phospho-specific antibody against Thr residue 
in the activation loop. We treated HeLa cells with various concentrations of either TIM-063 or its 
inactive analogues TIM-062 and TIM-064. It is noteworthy that TIM-064 exhibited a cytotoxic 
effect, indicating the off-target effect of the compound. Thus, we thereafter used TIM-062 as an 
inactive compound. When we applied various concentrations of TIM-063 to HeLa cells, 1 µM 
ionomycin-induced Thr172 phosphorylation of endogenous AMPKα was inhibited by TIM-063 
in a dose-dependent manner but was not affected by up to 29 µM of TIM-062 (Fig. 4A). To test 
the inhibitory effect of TIM-063 on the phosphorylation of other CaMKK targets, CaMKI and 
CaMKIV, we transfected a hemagglutinin (HA)-tagged either CaMKIα or CaMKIV expression 
vector into HeLa cells and subsequently treated the cells with 1 µM ionomycin for 5 min (Fig. 4B 
and C). We then analyzed the phosphorylation of Thr177 in HA-CaMKIα (Fig. 4B) and Thr196 
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in HA-CaMKIV (Fig. 4C). In a similar manner to the inhibition of AMPK phosphorylation, 
endogenous CaMKK-mediated phosphorylation of exogenously expressed HA-CaMKIα (at 
Thr177) and HA-CaMKIV (at Thr196) was suppressed by TIM-063 in a dose-dependent manner 
but not by the inactive analogue, TIM-062 up to 29 µM (Fig. 4B and C). TIM-063 at 2.6 µM 
significantly suppressed (>80 % inhibition) the phosphorylation of endogenous AMPKα and 
exogenously expressed CaMKI and CaMKIV in ionomycin-stimulated HeLa cells (IC50 = ~0.3 
µM) as its inhibition of the CaMKK isoforms in vitro (Fig. 2A and Fig. 3B). Thus, these results 
show that TIM-063 but not an inactive analogue (TIM-062), is capable of inhibiting endogenous 
CaMKK activity in intact cells as well as in vitro. 
 
Inhibition of CaMKK Isoforms-Catalyzed CaMKIV Phosphorylation by TIM-063 in 
Transfected COS-7 Cells.  To test the effect of TIM-063 on CaMKK isoforms-dependent 
phosphorylation of CaMKIV (at Thr196) in cultured cells, we transfected a HA-CaMKIV 
expression vector into COS-7 cells together with either FLAG-CaMKKα (Fig. 5A) or CaMKKβ 
(Fig. 5B)-expression vectors and subsequently stimulated the cells with 1 µM ionomycin for 5 min. 
We then analyzed the phosphorylation of Thr196 in HA-CaMKIV (Fig. 5). Phosphorylation of 
HA-CaMKIV was induced by co-transfection with either FLAG-CaMKKα or CaMKKβ. In a 
similar manner to the inhibition of endogenous CaMKK activity in HeLa cells (Fig. 4A and B), 
both CaMKKα- and CaMKKβ-induced HA-CaMKIV phosphorylation were significantly 
inhibited by 26 µM TIM-063 treatment, indicating that TIM-063 suppressed activities of both 
exogenously expressed CaMKK isoforms in cultured cells. It is noteworthy that up to 29 µM TIM-
062 did not affect the phosphorylation of HA-CaMKIV by CaMKK isoforms. 
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DISCUSSION 
   We synthesized STO-609 derivatives and found a novel CaMKK inhibitor, TIM-063. In 
contrast to STO-609 that is approximately 5–10-fold more effective in inhibiting CaMKKβ than 
CaMKKα (Fig. 1A) (32), TIM-063 suppresses CaMKK isoforms with an similar potency (Ki = 
0.2–0.35 µM), indicating that TIM-063 is a pan-CaMKK inhibitor (Figs. 1 and 2). Similarly to 
STO-609, TIM-063 directly inhibited CaMKK in an ATP-competitive manner. This novel 
CaMKK inhibitor penetrated the cell membrane, resulting in the suppression of ionomycin-
induced phosphorylation of endogenous AMPK at Thr172 and exogenously expressed CaMKIα 
at Thr177 and CaMKIV at Thr196, which were mediated by endogenous CaMKK in cultured cells 
with an IC50 of ~0.3 µM (Fig. 4). This is consistent with the results that TIM-063 inhibited 
exogenously expressed CaMKKα and CaMKKβ-mediated CaMKIV phosphorylation in 
transfected cells (Fig. 5) although inhibition of exogenously expressed CaMKKs requires higher 
concentration of TIM-063 than that of endogenous CaMKKs as shown in Fig. 4. This is probably 
due to high concentration of transiently expressed CaMKK isoforms in the cells. Other STO-609 
derivatives synthesized with replacement of the only carboxylic acid group at position R2 by 
various substituents (TIM-055, -057, -059, -060) were inactive possibly due to steric hindrance 
caused by bulky substituents and only TIM-063 with a hydroxy group at position R1 and a nitro 
group at position R2 possessed CaMKK inhibitory activity (Fig. 1). Both TIM-062 lacking a nitro 
group at position R2 and TIM-064 lacking a hydroxy group at position R1 were unable to suppress 
CaMKK activity in vitro or in cultured cells, indicating that both substituents are required for the 
CaMKK inhibitory activity of TIM-063. Whereas TIM-064 exhibits a cytotoxic effect, TIM-062 
is an inactive analogue in vitro as well as in cultured cells without a cytotoxic effect; thus, TIM-
062 would be helpful to evaluate the pharmacological effect of TIM-063 as a CaMKK inhibitor. 
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The 2.4 Å crystal structure of the catalytic domain of human CaMKKβ complexed with STO-609 
revealed mostly hydrophobic interactions between STO-609 and CaMKKβ (49). Furthermore, it 
has been shown that STO-609 forms hydrogen bonds with the backbones atoms of human 
CaMKKβ Val270 and Asp330, as well as Glu236 in a water-mediated manner (49). These 
interactions make the carboxylic acid moiety of STO-609 slightly tilted, resulting in the inhibitor 
fitting within a narrow pocket of the CaMKKβ catalytic domain that adopts a closed conformation 
(49). In contrast to STO-609, which preferably inhibits CaMKKβ rather than CaMKKα (32), 
replacement of the carboxylic acid group at position R2 by a nitro group in TIM-063 may cause a 
conformational change, resulting in an equal inhibitory potency of TIM-063 against both CaMKK 
isoforms. Furthermore, the hydroxy group at position R1 in TIM-063 may form an additional 
hydrogen bond with CaMKKs or increase the electron density of the nitro group by resonance 
effects, resulting in enhancement of hydrogen bonds with CaMKK isoforms to stabilize the 
inhibitor/CaMKK complex formation. Therefore, structural determination of the CaMKK/TIM-
063 complex remains to be done for detailed analyses of CaMKK inhibition by TIM-063. This 
study also indicates that STO-609 and TIM-063 might be promising lead compounds for the 
development of a new therapeutically useful CaMKK inhibitor. Although a novel CaMKK 
inhibitor (TIM-063) in combination with structurally related inactive compound (TIM-062) could 
be helpful to evaluate the physiological significance(s) of CaMKK-mediated signaling cascades in 
vivo, the inhibitor should be used for that purpose carefully and cautiously because the specificity 
of the inhibitor has not become completely clear. 
 
ASSOCIATED CONTENT 
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: Synthesis of TIM-063 and its derivatives (MS Word file) 
Supplemental Figure S2 
: Dixon plot of CaMKK inhibition by TIM-063 (TIF file) 
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Notes 





CaM, calmodulin; CaMK, Ca2+/CaM-dependent protein kinase; HA, hemagglutinin; CaMKKα, β, 
Ca2+/CaM-dependent protein kinase kinase α, β; AMPK, 5’AMP-activated protein kinase; TIM-
063, 2-hydroxy-3-nitro-7H-benzo[de]benzo[4,5]imidazo[2,1-a]isoquinolin-7-one; STO-609, 7H-
benzimidazo[2,1-a]benz[de]isoquinoline-7-one-3-carboxylic acid; PKA, cAMP-dependent 
protein kinase; PKB, protein kinase B 
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Table 1. Inhibitory profile of various protein kinases by TIM-compounds 
 
 
                 IC50 value (% inhibition at 10 µg/mL) 
Protein kinases    TIM-062   TIM-063    TIM-064 
 
CaMKKα    > 29 µM (18 ± 3 %)  0.63 µM      > 27 µM (4 ± 3 %) 
CaMKKβ    > 29 µM (15 ± 5 %)  0.96 µM      > 27 µM (1 ± 4 %) 
CaM kinase I    > 29 µM (22 ± 12 %)    > 26 µM (32 ± 6 %)     > 27 µM (9 ± 4 %) 
CaM kinase II    > 29 µM (14 ± 12 %)   14 µM      > 27 µM (26 ± 8 %) 
CaM kinase IV    > 29 µM (ND) a    > 26 µM (8 ± 6 %)     > 27 µM (ND) 
PKAb     > 29 µM (17 ± 5 %)    > 26 µM (24 ± 2 %)     > 27 µM (29 ± 9 %) 
 
aND, not detected; bPKA, cAMP-dependent protein kinase 
10 µg/mL compounds (TIM-062: 29 µM, TIM-063: 26 µM, TIM-064: 27 µM) 
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Figure Legends 
Figure 1. Characterization of STO-609 derivatives as CaMKK inhibitors. A. Chemical 
structure of STO-609 and its derivatives with different substitutions at positions R1, R2, and R3. B. 
Protein kinase activities of CaMKKα (open column) and β (closed column) were measured at 30°C 
for 10 min in a solution containing 50 mM HEPES pH 7.5, 10 mM Mg(CH3COO)2, 1 mM DTT, 
12.5 µg GST-CaMKI 1–293 Lys49Glu, 100 µM [γ-32P]ATP and 2 mM CaCl2/6 µM CaM in the 
absence (5% DMSO) or presence of 10 µg/mL STO-609 or its derivatives (TIM-055–064) as 
described in the “MATERIALS AND METHODS.” CaMKK activities are quantitated and 
expressed as a percentage of the average value in the absence of compound. Results are represented 
as the mean ± S.D. from triplicate experiments. Error bars represent S.D. 10 µg/mL compounds 
(STO-609: 27 µM, TIM-055: 30 µM, TIM-056: 30 µM, TIM-057: 28 µM, TIM-058: 28 µM, TIM-
059: 28 µM, TIM-060: 30 µM, TIM-061: 30 µM, TIM-062: 35 µM, TIM-063: 30 µM, TIM-064: 
32 µM ) 
 
Figure 2. Effect of TIM-063 and its analogues on the activities of CaMKK isoforms. A. Protein 
kinase activities of CaMKKα (left panel) and CaMKKβ (right panel) were measured at 30°C for 
10 min in a solution containing 50 mM HEPES pH 7.5, 10 mM Mg(CH3COO)2, 1 mM DTT, 12.5 
µg GST-CaMKI 1–293 Lys49Glu, 100 µM [γ-32P]ATP and 2 mM CaCl2/6 µM CaM in the absence 
(5% DMSO) or presence of indicated concentrations of STO-609 (open circle), TIM-062 (closed 
triangle), TIM-063 (closed circle), and TIM-064 (closed diamond). CaMKK activities are 
quantitated and expressed as a percentage of the average value in the absence of compound. Results 
are represented as the mean ± S.D. from triplicate experiments. Error bars represent S.D. B. 
Autophosphorylation of CaMKKα (right panel) and CaMKKβ (left panel) was measured at 30°C 
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for 120 min in a solution containing 1 µg CaMKK isoforms, 50 mM HEPES pH 7.5, 10 mM 
Mg(CH3COO)2, 1 mM DTT, 100 µM [γ-32P]ATP in the presence of 2 mM CaCl2/6 µM CaM (for 
CaMKKα) or 2 mM EGTA (for CaMKKβ) as described in the “MATERIALS AND METHODS” 
in the absence (5% DMSO) or presence of indicated concentrations (0.26–26 µM) of TIM-063 
(closed circle) as duplicate experiments. C. CaMKKα (right panel) and CaMKKβ (left panel) 
autophosphorylation were measured at 30°C for 120 min as described in panel B in the absence 
(DMSO) or presence of 10 µg/mL of TIM-062 (29 µM) and TIM-064 (27 µM). The 
autophosphorylation was quantitated and expressed as a percentage of the average value in the 
absence of compounds. Results are represented as an average ± S.D. from triplicate experiments. 
Error bars represent S.D. Statistical differences are marked: *p < 0.05; n.s., not significant versus 
autophosphorylation in the absence of compounds (DMSO). Insert, autoradiograms of the 
CaMKKα (B, left panel) and CaMKKβ (B, right panel) autophosphorylation in the absence or 
presence of TIM-063 (0.26–26 µM). The molecular mass in kilodaltons (kDa) is indicated on the 
left. An asterisk in each panel indicates CaMKK autophosphorylation. 
 
Figure 3. TIM-063, an ATP-competitive CaMKK inhibitor. A. Activities of CaMKKα full-
length enzyme (left panel, closed circle), CaMKKα catalytic domain mutant (GST-CaMKKα 126-
434, left panel, open circle), CaMKKβ full-length enzyme (right panel, closed circle), CaMKKβ 
catalytic domain mutant (GST-CaMKKβ 162-470, right panel, open circle) were measured at 
30°C for 10 min in a solution containing 50 mM HEPES pH 7.5, 10 mM Mg(CH3COO)2, 1 mM 
DTT, 12.5 µg GST-CaMKI 1–293 Lys49Glu, 100 µM [γ-32P]ATP and 2 mM CaCl2/6 µM CaM in 
the absence (5% DMSO) or presence of indicated concentrations of TIM-063 with either 2 mM 
CaCl2/6 µM CaM (for CaMKK full-length enzymes) or 2 mM EGTA (for CaMKK catalytic 
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domain mutants). CaMKK activities were quantitated, expressed as a percentage of the average 
value in the absence of TIM-063, and plotted as duplicate experiments. B. Protein kinase activities 
of CaMKKα (left panel) and CaMKKβ (right panel) were measured at 30°C for 10 min in a 
solution containing 50 mM HEPES pH 7.5, 10 mM Mg(CH3COO)2, 1 mM DTT, 12.5 µg GST-
CaMKI 1–293 Lys49Glu, and 2 mM CaCl2/6 µM CaM with various concentrations (25–200 μM) 
of [γ-32P]ATP in either the absence (open circle) or presence of 0.84 µM TIM-063 (closed circle). 
CaMKK activities were presented as double reciprocal plots (Lineweaver–Burk) from duplicate 
experiments. 
 
Figure 4. Effect of TIM-063 on ionomycin-induced phosphorylation of endogenous AMPKα, 
exogenously expressed CaMKIα and CaMKIV in HeLa cells. Either HeLa cells (A) , HA-
CaMKIα expression vector (1 µg)-transfected HeLa cells (B), HA-CaMKIV expression vector 
(0.25 µg)-transfected HeLa cells (C) were cultured in 6-well dishes in the absence of serum for 6 
h without (0) or with indicated concentrations (0.26, 2.6, 26 µM) of TIM-063 or 29 µM TIM-062, 
and then stimulated without (-) or with (+) 1 µM ionomycin (iono) for 5 min as described in the 
“MATERIALS AND METHODS.”  Subsequently, cell lysates were subjected to immunoblot 
analysis using either an anti-pAMPKα (at Thr172) antibody (panel A, inset upper panel, an arrow), 
anti-AMPKα antibody (panel A, inset lower panel, an asterisk), anti-pCaMKIα (at Thr177) 
antibody (panel B, inset upper panel, an arrow), anti-pCaMKIV (at Thr196) antibody (panel C, 
inset upper panel, an arrow), or anti-HA antibody (panel B and C, inset lower panel, an asterisk). 
The phosphorylation levels of AMPKα at Thr172 (panel A), HA-CaMKIα at Thr177 (panel B) 
and HA-CaMKIV at Thr196 (panel C) was quantitated, expressed as a percentage of the average 
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value of stimulated cells with 1 μM ionomycin without compounds, and plotted as duplicate 
experiments. 
 
Figure 5. Inhibition of CaMKK isoforms-mediated CaMKIV phosphorylation by TIM-063 
in transfected COS-7 cells. COS-7 cells in 6-well dishes were transfected with HA-CaMKIV 
expression vector (1 µg) without (-) or with FLAG-CaMKKα (A) or CaMKKβ (B) expression 
vector (0.5 µg) followed by culturing in the absence of serum for 6 h without (-) or with indicated 
concentrations (0.26, 2.6, 26 µM) of TIM-063 or 29 µM TIM-062, and then treated with 1 µM 
ionomycin for 5 min as described in the “MATERIALS AND METHODS.” Subsequently, the 
cell lysates were subjected to immunoblot analysis using either an anti-pCaMKIV (at Thr196) 
antibody (inset upper panels, arrows) or anti-HA antibody (inset lower panels, asterisks). The 
phosphorylation levels of HA-CaMKIV at Thr196 were quantitated, expressed as a percentage of 
the average value of stimulated cells with 1 μM ionomycin without compounds, and plotted as 
duplicate experiments. 
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Figure 1. Characterization of STO-609 derivatives as CaMKK inhibitors. 
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Figure 2. Effect of TIM-063 and its analogues on the activities of CaMKK isoforms. 
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Figure 3. TIM-063, an ATP-competitive CaMKK inhibitor. 
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Figure 4. Effect of TIM-063 on ionomycin-induced phosphorylation of endogenous 
AMPKα, exogenously expressed CaMKIα and CaMKIV in HeLa cells. 
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Figure 5. Inhibition of CaMKK isoforms-mediated CaMKIV phosphorylation by TIM-063 
in transfected COS-7 cells. 
  
                                                






Scheme 1. Synthesis of TIM-063 and its analogues 
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Supporting Information S1 
 
Synthesis of TIM-063 
A mixture of 3-hydroxy-1,8-naphthalenedicaroxylic anhydride 1 (300 mg, 1.40 mmol), ammonium 
nitrate (1212 mg, 14.0 mmol) in dichloromethane (7.5 mL) was added trifluoroacetic anhydride (0.4 mL, 
2.80 mmol) at room temperature. The suspension was stirred at room temperature for 6 h. The mixture 
was filtered through a celite pad using ethyl acetate and the filtrate was concentrated to give a brown oil, 
which was purified by column chromatography on silica gel (ethyl acetate/hexane) to yield 
3-hydroxy-4-nitro-1,8-naphthalenedicaroxylic anhydride 2 as a yellow solid (176 mg, 0.68 mmol, 49%). 
A mixture of 2 (176 mg, 0.68 mmol) and 1,2-phenylenediamine (81 mg, 0.75 mmol) in THF (6 mL) 
was heated under refluxing for 24 h and cooled to room temperature. The obtained precipitate was filtered 
and washed with THF to yield pure TIM-063 as a yellow solid (149 mg, 0.45 mmol, 66%). 
1H NMR (300 MHz, DMSO-d6) d 5.15-5.35 (br, 1H), 6.55 (dt, 1H, J = 1.5, 7.9 Hz), 6.72 (dd, 1H, J = 1.5, 
8.2 Hz), 6.98 (dd, 1H, J = 1.5, 7.9 Hz), 7.19 (dt, 1H, J = 1.5, 8.2 Hz), 7.92 (dd, 1H, J = 7.3, 8.5 Hz), 8.02 
(dd, 1H, J = 1.2, 8.5 Hz), 8.20 (s, 1H), 8.33 (dd, 1H, J = 1.2, 7.3 Hz). 13C NMR (75 MHz, DMSO-d6) d 
116.1. 116.2, 120.8, 122.8, 123.2, 124.8, 125.3, 126.1, 127.7, 128.8, 129.9, 130.4, 130.8, 137.0, 146.4, 
149.0, 163.0, 163.9. ESI-MS, m/z: 332 (M++1). 
 
Preparation of acetic acid salt of TIM-063 
A mixture of TIM-063 (60 mg, 0.18 mmol) and acetic acid (1 mL) in THF (10 mL) was heated at 
60°C for 1h, and concentrated in vacuo to yield acetic acid salt of TIM-063 as an orange solid (65 mg). 
The obtained salt was used without further purification. 
 
TIM-062 and TIM-064, and their acetic acid salts were prepared by a similar procedure for the synthesis 
of TIM-063. 
 
TIM-062 (yellow solid, 65%) 
1H NMR (300 MHz, DMSO-d6) d 5.19-5.22 (br, 1H), 6.56 (dt, 1H, J = 1.5, 7.9 Hz), 6.73 (dd, 1H, J = 1.5, 
8.2 Hz), 6.93 (dd, 1H, J = 1.5, 7.9 Hz), 7.07 (dt, 1H, J = 1.5, 8.2 Hz), 7.62 (d, 1H, J = 2.3 Hz), 7.74 (dd, 
1H, J = 7.3, 8.2 Hz), 7.98 (d, 1H, J = 2.3 Hz), 8.20 (d, 1H, J = 7.3 Hz), 8.22 (d, 1H, J = 8.2, Hz). 13C 
NMR (75 MHz, DMSO-d6) d 116.1, 116.2, 116.3, 121.4, 122.4, 124.0, 124.2, 125.7, 127.9, 128.0, 129.7, 
130.5, 133.0, 134.4, 145.5, 156.9, 164.1, 164.4. ESI-MS, m/z: 287 (M++1). 
 
TIM-064 (orange solid, 68%) 
1H NMR (300 MHz, DMSO-d6) d 5.26-5.36 (br, 1H), 6.56 (dt, 1H, J = 1.5, 7.9 Hz), 6.73 (dd, 1H, J = 1.5, 
8.2 Hz), 7.01 (dd, 1H, J = 1.5, 7.9 Hz), 7.10 (dt, 1H, J = 1.5, 8.2 Hz), 8.10 (dd, 1H, J = 7.2, 8.4 Hz), 8.56 
(s, 2H), 8.60 (d, 1H, J = 7.2 Hz), 8.72 (d, 1H, J = 8.4 Hz). 13C NMR (75 MHz, DMSO-d6) d 116.2, 116.3, 
120.7, 123.7, 124.9, 125.1, 129.0, 129.2, 129.9, 130.0, 130.1, 130.4, 130.7, 132.1, 146.5, 149.9, 163.0, 
163.8. ESI-MS, m/z: 316 (M++1). 
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